1392113-73-3Relevant academic research and scientific papers
Amphiphilic tobramycin analogues as antibacterial and antifungal agents
Shrestha, Sanjib K.,Fosso, Marina Y.,Green, Keith D.,Garneau-Tsodikova, Sylvie
, p. 4861 - 4869 (2015/09/01)
In this study, we investigated the in vitro antifungal activities, cytotoxicities, and membrane-disruptive actions of amphiphilic tobramycin (TOB) analogues. The antifungal activities were established by determination of MIC values and in time-kill studie
Tobramycin Variants with Enhanced Ribosome-Targeting Activity
Fosso, Marina Y.,Zhu, Hongkun,Green, Keith D.,Garneau-Tsodikova, Sylvie,Fredrick, Kurt
, p. 1565 - 1570 (2015/07/27)
With the increased evolution of aminoglycoside (AG)-resistant bacterial strains, the need to develop AGs with 1) enhanced antimicrobial activity, 2) the ability to evade resistance mechanisms, and 3) the capability of targeting the ribosome with higher ef
Design of membrane targeting tobramycin-based cationic amphiphiles with reduced hemolytic activity
Herzog, Ido M.,Feldman, Mark,Eldar-Boock, Anat,Satchi-Fainaro, Ronit,Fridman, Micha
, p. 120 - 124 (2013/03/13)
Tobramycin-based cationic amphiphiles differing in the chemical bond linking their hydrophobic and hydrophilic parts were synthesized and biologically evaluated. Several compounds demonstrated potent antimicrobial activities compared to the parent drug. One analogue exhibited a significant reduction in red blood cells hemolysis, demonstrating that it is possible to maintain the antimicrobial potency of these molecules while reducing their undesired hemolytic effect through chemical modifications. The Royal Society of Chemistry 2013.
6″-thioether tobramycin analogues: Towards selective targeting of bacterial membranes
Herzog, Ido M.,Green, Keith D.,Berkov-Zrihen, Yifat,Feldman, Mark,Vidavski, Roee R.,Eldar-Boock, Anat,Satchi-Fainaro, Ronit,Eldar, Avigdor,Garneau-Tsodikova, Sylvie,Fridman, Micha
, p. 5652 - 5656 (2012/08/28)
Amphiphilic tobramycin analogues with potent antibacterial activity against tobramycin-resistant bacteria were synthesized. Most analogues were found to be less prone to deactivation by aminoglycoside-modifying enzymes than tobramycin. These compounds tar
